ARCHIVES

FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”

This article is from The Cancer Letter archive.

Vol. 02 No. 36 | September 3, 1976

Download PDF Visit The Full Archive

Related Articles

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

March 29, 2013

NCI Hires Harold Freeman To Direct New Center For Study Of Health Disparities.

June 16, 2000

NCI Intramural Research: More Than 200 Scientists At Frederick To Become NCI Employees This Year

March 26, 1999

Nixon National Cancer Conference Kicks Off

December 8, 2021

DCT Board Okays Six Contract Recompetitions

October 23, 1987

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008